Effects of Metformin on the serum PCSK9 in patients with type 2 diabetes mellitus
10.3969/j.issn.1006-6187.2017.01.013
- VernacularTitle:二甲双胍对2型糖尿病患者血清前蛋白转化酶枯草溶菌素9水平的影响
- Author:
Lei JIAN
;
Jingfang PAN
- Keywords:
Diabetes mellitus,type 2;
Proprotein convertase subtilisin/kexin type 9 (PCSK9 );
Met-formin
- From:
Chinese Journal of Diabetes
2017;25(1):58-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of Metformin on serum proprotein convertase subtilisin/kexin type 9(PCSK9)level in patients with type 2 diabetes(T2DM). Methods 48 healthy people with normal glucose tolerance were selected as the controls (NGT group). 93 newly diagnosed T2DM were randomized to Metformin treated group (Met,n= 47 )and Glipizide treated group (Gli,n=46).Serum PCSK9 was measured by ELISA in all participants. After treatment,the changes of serum PCSK9 were observed in Met group and Gli group. Results Serum PCSK9 levels in Met group and Gli group were higher than NGT group(P<0. 01). PCSK9 level was positively correlated with FPG,HbA1 c, HOMA-IR,FIns,TC,LDL-C,TG,hsC-RP,TNF-αand BMI (r= 0. 578,0. 638,0. 556,0. 610,0. 578, 0. 592,0. 589,0. 638,0. 561,0. 552;P<0. 05 or P<0. 01),and negatively correlated with HDL-C(r=-0. 614,P<0. 01). The levels of PCSK9 significantly decreased after treatment with Metformin(P<0. 05). PCSK9 levels had no significant differences before and after treatment with Glipizide. Multiple regression analysis showed that TNF-αand HOMA-IR were independent related factors of PCSK9. Conclusion T2DM patients have high levels of serum PCSK9 which can be decreased by Metformin.
